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The structures of NPAMOZ and the haptens were initially drawn in HyperChem 7.0 
software (Hypercube, Inc., USA). The most stable conformations were optimized using 
Hartree-Fock (HF) with a 6-31G* basis set in the Gaussian 03 package (revision B.05, 
Gaussian, Inc., USA). The alignment of haptens and NPAMOZ was completed by SYBYL7.3 



























For ELISA analysis, the extract was diluted three times with the PBS assay buffer. For LC-
MS/MS analysis, the extract was filtered with a microporous membrane (0.45 μm) prior to 
use. An Agilent ZORBAX SB-C18 (2.1×150 mm, 3.5 µm particle size) column was used. 
Mobile phase A consisted of 0.1% formic acid in water and mobile phase B was acetonitrile. 
The following gradient profile: 0 min, 22% B; 0–6 min, 22–99% B; 6–9 min, 99%B; 9–9.1 
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min, 99–22% B; 9.1–15 min, 22% B. The flow rate of the mobile phase was 0.3 mL min–1 and 
an aliquot of 5 µL of each sample was injected into the LC system. Analytes were determined 
by ESI-MS/MS in positive mode. The parameters were as follows: gas temperature, 350 °C; 
gas flow, 10 L min–1; nebulizer gas, 35 psi; capillary voltage, 4.0 kV. High-purity nitrogen 






























































































































































Fish, shrimp, chicken and pork samples with a confirmed absence of AMOZ were spiked at 
three different concentrations (1.0, 5.0 and 20.0 μg kg–1) with AMOZ and analyzed by the 
developed ciELISA. The results were validated with the standard LC-MS/MS. For ciELISA 
analysis, the sample exacts were first determined without further pretreatment. Slightly lower 
recoveries (average of 74.7% and ranging from 68.5% to 81.2%, Table 3) were obtained. In 
contrast, good recoveries (average of 94.9% and ranging from 79.5% to 107.2%, Table 3) 
were obtained for the standard LC-MS/MS analysis. The comparative lower recovery for the 
ciELISA analysis maybe due to the trace amounts of solvent (hexane) left in the sample 
extract. On dilution of the sample exacts with PBS the recoveries were tested again. The 
results indicated that good recoveries (average of 91.1% and ranging from 81.5% to 102.3%, 
Table 3) were obtained when three dilutions with PBS were performed. Following the 
correction of the data by a dilution factor of three, the LOD and linear range of the developed 
ciELISA for AMOZ in fish and shrimp samples were 0.3 μg kg–1 and 0.9 to 105.3 μg kg–1, 
respectively. The LOD of this assay can satisfy the MRPLs (1 μg kg–1) for AMOZ set by the 
EU. 
The ciELISA was then applied to determine AMOZ residue in market samples. Twenty 
samples (including five fish samples (#1 to #5), five shrimp samples (# 6 to # 10), five 
chicken samples (#11 to #15) and five pork samples (#16 to #20)) were collected from the 
markets nearby the South China Agricultural University. One shrimp sample (#7) was found 
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AMOZ positive (3.4 μg kg–1 by ciELISA). The following HPLC-MS/MS analysis gave 
AMOZ value of 4.2 μg kg–1. No false positive and negative results were obtained in the 
screening test. It indicated that the assay is ideally suited as a screening method for AMOZ 
residue prior to chromatographic analysis.  
4. Conclusions 
Two novel immunizing haptens (derivatised 3-amino-5-morpholinomethyl-2-oxazolidinone 
with 2-(4-formylphenoxy)acetic acid or 2-(3-formylphenoxy)acetic acid) were designed and 
coupled to bovine serum albumin as immunogens to raise antibodies aginst the nitrophenyl 
derivative of furaltadone metabolite 3-amino-5-morpholinomethyl-2-oxazolidinone 
(NPAMOZ). New Zealand rabbits were immunized with the immunogens and polyclonal 
antibodies specific to NPAMOZ were obtained. The results indicated antibodies produced 
against the novel immunizing haptens showed higher sensitivity in competitive indirect 
enzyme-linked immunosorbent assay (ciELISA) compared to antibodies produced against the 
traditional immunizing haptens (derivatised 3-amino-5-morpholinomethyl-2-oxazolidinone 
with 3-carboxybenzaldehyle or 4-carboxybenzaldehyle). Molecular modeling was used to 
optimize the lowest energy conformations of NPAMOZ and the immunizing haptens. The 
results indicated that the two novel haptens had better alignments with NPAMOZ than the 
two traditional haptens. A novel heterologous coating hapten was also synthesized 
derivatising 3-amino-5-morpholinomethyl-2-oxazolidinone with 2-oxoacetic acid. Marked 
improvement on assay sensitivity was observed when using a heterologous ELISA assay 
format, which suggested that the strategy of using only a partial structure of the target 
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molecule as the coating hapten can improve the assay sensitivity. The ciELISA based on the 
optimal antibody and coating antigen showed an IC50 of 6.3 μg L–1, the limit of detection 
(LOD) of 0.3 μg L–1 and the linear range of 0.9–105.3 μg L–1 for NPAMOZ in animal 
samples. Thus the LOD of this assay can satisfy the MRPLs (1 μg kg–1) for AMOZ in food of 
animal origin set by the EU. These results indicated that the proposed ELISA, with high 
sensitivity and specificity, as well as good reproducibility and accuracy, is ideally suited as a 
monitoring method for AMOZ residues at trace levels. Subsequently, effort will be made on 
the screening of monoclonal antibodies against NPAMOZ from mice immunized with the 
novel immunogen (hapten 4-BSA). 
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R215  55.6±4.4  45.4±4.1  35.2±2.8  31.7±3.6 17.1±1.5 
Hapten 2‐
BSA 
R217  35.7±3.2  51.3±6.0  28.3±2.7  33.4±3.9  14.3±2.3 
Hapten 3‐
BSA 
R220  29.0±2.6  24.2±2.5 32.1±2.5 20.6±1.8 9.9±1.1 
Hapten 4‐
BSA 












Competitor  IC50 (μg L
–1) CR a (%) 
NPAMOZ  2.1±0.14 100 
NPAOZ, NPSEM, NPAHD  >10 000 <0.02 
AMOZ  89.7±9.4 2.3 
AOZ, SEM, AHD  >10 000 <0.02 
Furaltadone  6.1±4.6 34.4 
Nitrofurantoin, nitrofurazone, furazolidone >10 000 <0.02 
o‐NBA  >10 000 <0.02 
Ciprofloxacin  >10 000 <0.02 
Enrofloxacin  >10 000 <0.02 


































1.0  74.0  11.3 82.4 12.8 97.4  5.6
5.0  69.5  13.9 88.0 10.3 89.6  10.9
20.0  71.2  14.6 95.6 15.1 105.6  7.6.
Shrimp  
1.0  73.4  11.5 81.5 12.7 107.2  6.3
5.0  70.1  16.2 97.3 11.6 82.7  4.4
20.0  77.6  13.9 85.7 8.9 95.4  8.0
Chicken 
1.0  80.3  9.7 91.6 11.6 79.5  11.3
5.0  74.2  15.0 102.3 10.7 103.2  8.6
20.0  79.1  11.3 95.5 9.8 95.4  9.0
Pork 
1.0  68.5  15.2 91.6 15.6 97.3  7.9
5.0  81.2  9.8 87.9 13.4 98.8  10.1































































































































































NPAMOZ (μ g L-1)






represents the average of three replicates and the standard deviation of the mean. 
 
Highlights 
 
> Several novel haptens against furaltadone metabolite AMOZ were synthesized. 
> Polyclonal antibodies against the novel haptens were generated. 
> Improved sensitivity was observed for the antibodies in ELISA. 
> Molecular modeling of haptens structure was used to explain the results. 
> Application of ELISA in real sample indicated good reproducibility and accuracy. 
> The assay is ideally suited as a monitoring method for AMOZ residues at trace level. 
